TBC,

Boston,

MA,

US,

ZIP: 02203

Phone: +1 6174554188

The hotly anticipated mRNA-Based Therapeutics Summit is returning in-person for its second year this July and will deliver exclusive data from the movers and shakers in mRNA vaccine and therapy development. 400+ industry pioneers from the likes of Pfizer, Moderna, Sanofi, and Arcturus Therapeutics are reuniting at the world’s only end-to-end meeting focused on the development of mRNA vaccines and therapies from early basic research through to commercialization and patients in need.

Expect 70+ world-class speakers from large pharma, innovative biotechs, and KOLs of academia, dedicated tracks and 3 days of immersive content on discovery, pre-clinical & clinical development, manufacturing, analytical development, and supply chain & logistics. Join us in Boston to accelerate platforms for efficacious mRNA-based therapeutics and vaccines in oncology, infectious, rare diseases, and beyond.

Download your copy of the event guide to see all speakers and presentations here: https://bit.ly/3t1DFFR

Tickets    https://go.evvnt.com/1037456-2?pid=1052
Brochure https://go.evvnt.com/1037456-3?pid=1052

Prices:
Drug Developer Pricing - Conference + Focus day USD 2998.00,
Drug Developer Pricing - Conference Only USD 2099.00,
Academic Pricing - Conference + Focus Day USD 2398.00,
Academic Pricing - Conference Only USD 1699.00,
Solution Provider Pricing - Conference + Focus Day USD 3798.00,
Solution Provider Pricing - Conference Only USD 2699.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Kathy Fernando, VP, Head of Worldwide Research, Development and Medical Operations & Head of mRNA Scientific Planning, Pfizer, Linda Marban, CEO, Capricor Therapeutics , Nathaniel Wang, CEO & Co-Founder, Yusuf Erkul, CEO, Kernal Biologics , Austin Boesch, Head of Protein Science, Tidal Therapeutics - A Sanofi Company , Gregory Fiore, CEO Exacis Biotherapeutics, John Marshall, Senior Director - Rare Disease, Moderna , Shigeki Miyake-Stoner, Director of R&D & Head of Technology, Replicate Bioscience, Dipendra Gyawali, Scientist, Analytical Development, Moderna, Kalina Paunovska, Postdoctoral Scholar, Georgia Institute of Technology, Dahlman Lab, Rachit Jain, Associate Director mRNA Process Development, Tessera Therapeutics, Yurong Guo, Associate Director, Analytical Development and QC, Arcturus Therapeutics, Ameya Kirtane, Instructor in Medicine, Brigham and Women’s Hospital, Mark van Eldijk, Principal Scientist Nanomedicine Development & Manufacturing, Ardena, Russell Johnson VP – Formulation Research, RVAC Medicines, Samuel Clarke, Director of R&D, Precision NanoSystems, Brett Leav, Head, Clinical Development, Public Health Vaccines, Moderna, Daniel G. Anderson, Medical Engineering & Science, Harvard-MIT Division of Health Sciences & Technology, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Haig Aghajanian, Co-Founder & VP of Research, Capstan Therapeutics, Hamideh Parhiz, Research Assistant Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, Joe Payne, Founder, President & CEO, Arcturus Therapeutics, Manmohan Singh, SVP - Pharmaceutical Sciences & Delivery Technologies, Beam Therapeutics, Sophia Shamsi, Research Analyst, Beacon Targeted Therapies, Venkat Krishnamurthy, Director & Senior Advisor - Genetic Medicine, Eli Lilly, Arun Kumar, Preclinical Vaccines Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI), Husain Attarwala, Director & Head, Pharmacometrics & Clinical Pharmacology, Moderna, Christopher Cheng, Executive Director - RNA Technology & Manufacturing, Verve Therapeutics, Duccio Medini, R3 Program Director, Wellcome Leap, David Liston, Senior Scientist, ReCode Therapeutics, Akhilesh Bhambhani, Senior Director - Biologics Drug Product Development; Tech Dev/Tech Ops, Ultragenyx Pharmaceutical, Metin Kurtoglu, COO, Cartesian Therapeutics, Tamar Grossman, Global Head - RNA & Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson, Hao Chen, Global Head of Cell & Viral Drug Substance, GlaxoSmithKline, Regis Gervier, Global Head, mRNA Center of Excellence, Sanofi, Prashant Yadav, Professor & Senior Fellow, INSEAD & Centre for Global Development, Rituparna Das, VP – COVID Vaccines, Moderna, Vishal Khanderia, Senior Director – Supply Chain, Beam Therapeutics, Michael Wourms, Senior Vice President, Head of mRNA Business Unit, Arranta Bio, Zoltán Kis, Assistant Professor, The University of Sheffield, Pervin Anklesaria, Deputy Director, HIV Vaccines & Biologics, Bill & Melinda Gates Foundation, Vittorio Sebastiano, Co-founder & Scientific Advisory Board Chairman, Turn Biotechnologies, Prashant Nambiar, SVP, Research & Translational Development, Strand Therapeutics, Camille Bedrosian, CMO & Executive VP, Ultragenyx , Arunan Kaliyaperumal, VP - Preclinical Biology, ReCode Therapeutics, Lior Zangi, Associate Professor of Cardiology; Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, Harris Makatsoris, Professor of Sustainable Manufacturing Systems, King’s College London, Charles Cabral, Drug Substance Manufacturing; Technology & Tech Transfer Director, Arcturus Therapeutics, Kirill Afonin, Professor of Chemistry, University of North Carolina at Charlotte, Jacob Becraft, Co-Founder & CEO, Strand Therapeutics, Jenny van Asbeck - van der Wijst, CEO, Mercurna, Stephanie Prizzon, Head of Analytical Sciences, mRNA Center of Excellence, Sanofi, Bowen Li, Assistant Professor, University of Toronto , Jianmei Kochling, Senior Director, Analytical Development mRNA Center of Excellence, Sanofi , Chantal Pichon, Professor, CNRS and University of Orléans, Gaurav Sahay, Associate Professor, Oregon State University, Husain Attarwala, Director & Head, Pharmacometrics & Clinical Pharmacology, Moderna, Arun Kumar, Preclinical Vaccines Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)